Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

UCB Completes $2.2B Acquisition of Candid Therapeutics to Advance BCMA T-Cell Engager for Autoimmune Diseases

Fineline Cube Jun 18, 2026
Company Deals

Eli Lilly Acquires 4E Therapeutics to Advance Next-Generation Chronic Pain Pipeline

Fineline Cube Jun 18, 2026
Company Deals

Xunfei Healthcare Partners with Sinar Mas Group to Deploy AI Medical Solutions Across Indonesia

Fineline Cube Jun 18, 2026
Company Deals

Alebund Pharmaceuticals Raises $163M in Hong Kong IPO to Advance Kidney Disease Pipeline

Fineline Cube Jun 18, 2026
Company Deals

Biogen to Acquire Immunology Specialist RayThera in $1 Billion Deal Targeting Anti-Inflammatory Pipeline

Fineline Cube Jun 18, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

Hotgen Biotech Secures NMPA Approval for SGT003 Bispecific Antibody Targeting Tumor Microenvironment

Fineline Cube Jun 18, 2026
Company Drug

GSK and Spero Therapeutics Secure FDA Approval for Utebzi, First Oral Carbapenem Antibiotic for Complicated UTIs

Fineline Cube Jun 18, 2026
Company Drug

Amgen’s Lumakras Combo Shows Promising Results in KRAS-mutated NSCLC Early-Stage Trial

Fineline Cube Sep 12, 2023

Amgen (NASDAQ: AMGN) has announced positive early-stage data for its KRASG12C inhibitor Lumakras (sotorasib) when...

Company Drug

Gilead’s Trodelvy Combo with MSD’s Keytruda Shows Promise in NSCLC Phase II Trial

Fineline Cube Sep 12, 2023

Gilead (NASDAQ: GILD) has announced interim data from a Phase II trial assessing the antibody-drug...

Company Deals

Wecare Medical Secures Pre-Series A Funding to Advance Brain Health Technology

Fineline Cube Sep 12, 2023

Hangzhou-based Wecare Medical, a developer of brain disease diagnosis, monitoring, and treatment products, has reportedly...

Company Deals

Sandoz Inks Deal with Samsung Bioepis for Ustekinumab Biosimilar SB17

Fineline Cube Sep 12, 2023

The Sandoz (SWX: SDZ) unit of Switzerland-based Novartis (NYSE: NVS) has announced the in-licensing of...

Policy / Regulatory

China Updates Narcotics and Psychotropic Substances Catalog, Adds Three Substances

Fineline Cube Sep 12, 2023

The National Medical Products Administration (NMPA), Ministry of Public Security, and National Health Commission have...

Company Drug

Sinovac Biotech Advances SA55 COVID-19 Neutralizing Antibody into Phase II Trials

Fineline Cube Sep 12, 2023

China-based vaccines firm Sinovac Biotech Ltd (NASDAQ: SVA) has announced the completion of a Phase...

Company Deals

Shanghai Haoyuan Chemexpress Aims to Raise RMB 1.16 Billion with Convertible Bonds

Fineline Cube Sep 12, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Shanghai Haoyuan Chemexpress Co., Ltd (SHA: 688131) has...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for HRS-7450 Acute Ischemic Stroke Study

Fineline Cube Sep 12, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

SinoMab BioScience Receives NMPA Approval for Phase I Study of Atopic Dermatitis Drug SM17

Fineline Cube Sep 12, 2023

Hong Kong-based biotechnology company SinoMab BioScience Ltd (HKG: 3681) has received approval from the National...

Company

Merck & Co. Becomes First Multinational to Register Unit in Hainan’s Lecheng Pilot Zone

Fineline Cube Sep 12, 2023

US pharmaceutical major Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK) has officially registered a...

Company Drug

Haisco Pharmaceutical Gets NMPA Approval for HSK21542 Chronic Pruritus Clinical Study

Fineline Cube Sep 12, 2023

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received approval...

Company Drug

ImmuneOnco’s IMM2510 and IMM27M Achieve Milestones in Phase I Clinical Trials

Fineline Cube Sep 12, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the completion of patient enrollment for...

Company Drug

CDE Indicates BTD Status for Visirna’s VSA001, Sperogenix’s Vamorolone, and Zai Lab’s Efgartigimod

Fineline Cube Sep 11, 2023

The Center for Drug Evaluation (CDE) website has indicated that Visirna Therapeutics’ novel siRNA therapy...

Company Deals

Shanghai Junshi Biosciences to Acquire Stake in Anlingke Biopharmaceutical for Cancer Therapy Programs

Fineline Cube Sep 11, 2023

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced its intention to...

Company Deals

Broncus Medical Inc. to Acquire Fibernova Holding Corporation for USD 2.7 Million

Fineline Cube Sep 11, 2023

Broncus Medical Inc., (HKG: 2216) a provider of lung disease precision intervention solutions with operations...

Company Medical Device

Lepu Medical Technology Receives NMPA Approval for MemoSorb Biodegradable PFO Occluder

Fineline Cube Sep 11, 2023

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...

Company Deals

EA Pharma and TransThera Sciences Collaborate on GI and Liver Disease Therapies

Fineline Cube Sep 11, 2023

Japan-based EA Pharma Co., Ltd and China-headquartered TransThera Sciences (Nanjing) Inc. have jointly announced the...

Company Deals

GRIT Biotechnology Secures RMB 400 Million in Series B Financing to Advance TIL Pipeline

Fineline Cube Sep 11, 2023

China-based GRIT Biotechnology has announced the completion of a Series B financing round, raising RMB...

Company Deals

Oriomics Secures Series B+ Funding to Advance Liver and Digestive Cancer Screening

Fineline Cube Sep 11, 2023

Hangzhou-based Oriomics, a specialist in cancer screening based on circulating tumor DNA (ctDNA) methylation detection,...

Company Drug

Sichuan Kelun Pharmaceutical Submits Biosimilar Cetuximab for NMPA Approval

Fineline Cube Sep 11, 2023

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), through its innovative drug development subsidiary Sichuan Kelun-Biotech...

Posts pagination

1 … 494 495 496 … 685

Recent updates

  • UCB Completes $2.2B Acquisition of Candid Therapeutics to Advance BCMA T-Cell Engager for Autoimmune Diseases
  • Eli Lilly Acquires 4E Therapeutics to Advance Next-Generation Chronic Pain Pipeline
  • Xunfei Healthcare Partners with Sinar Mas Group to Deploy AI Medical Solutions Across Indonesia
  • Hotgen Biotech Secures NMPA Approval for SGT003 Bispecific Antibody Targeting Tumor Microenvironment
  • GSK and Spero Therapeutics Secure FDA Approval for Utebzi, First Oral Carbapenem Antibiotic for Complicated UTIs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

UCB Completes $2.2B Acquisition of Candid Therapeutics to Advance BCMA T-Cell Engager for Autoimmune Diseases

Company Deals

Eli Lilly Acquires 4E Therapeutics to Advance Next-Generation Chronic Pain Pipeline

Company Deals

Xunfei Healthcare Partners with Sinar Mas Group to Deploy AI Medical Solutions Across Indonesia

Company Drug

Hotgen Biotech Secures NMPA Approval for SGT003 Bispecific Antibody Targeting Tumor Microenvironment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.